PureTech Health plc - 13 Jan 2022 Form 3 Insider Report for GELESIS HOLDINGS, INC. (CPSR)

Role
10%+ Owner
Signature
/s/ Daphne Zohar
Issuer symbol
CPSR
Transactions as of
13 Jan 2022
Net transactions value
$0
Form type
3
Filing time
21 Jan 2022, 15:30:14 UTC
Next filing
29 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GLSH Common Stock 16,727,582 13 Jan 2022 See footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GLSH Stock Option (Right to Buy) 13 Jan 2022 Common Stock 77,760 $4.05 See footnote F1, F2
holding GLSH Stock Option (Right to Buy) 13 Jan 2022 Common Stock 77,760 $4.05 See footnote F1, F3
holding GLSH Stock Warrant 13 Jan 2022 Common Stock 216,208 $0.0200 See footnote F1, F4
holding GLSH Earnout Shares 13 Jan 2022 Common Stock 4,526,622 See footnote F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 PureTech Health LLC directly holds all of the securities reported in this Form 3. PureTech Health plc is the parent company of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech Health LLC.
F2 The stock option is currently vested and exercisable.
F3 The stock option is currently vested and exercisable.
F4 The warrant is currently exercisable.
F5 On January 13, 2022, the reporting person received the right to acquire certain shares of the Issuer's Common Stock (the "Earnout Shares") pursuant to the Business Combination Agreement ("BCA") dated as of July 19, 2021, as amended on November 8, 2021, by and among Capstar Special Purpose Acquisition Corp., CPSR Merger Sub and Gelesis, Inc. ("Private Gelesis"). The Earnout Shares shall vest and be released upon the satisfaction of certain share price vesting conditions prior to January 13, 2027, as set forth in the BCA.